object
describ
immunolog
respons
clinic
outcom
coronaviru
sar
infect
healthcar
worker
hcw
administ
convalesc
plasma
treatment
method
convalesc
plasma
ml
obtain
three
sar
patient
transfus
three
infect
hcw
donor
blood
type
seroneg
hepat
b
c
hiv
syphili
human
tcell
lymphotrop
viru
type
ii
htlvi
ii
serum
antibodi
igg
titr
apharesi
perform
cs
plu
cell
separ
follow
form
convalesc
phase
plasma
part
routin
check
donat
plasma
convalesc
plasma
confirm
free
residu
sarscov
rtpcr
serial
serum
sampl
obtain
recipi
convalesc
plasma
collect
undertak
realtim
quantit
rtpcr
sarscov
direct
measur
viral
concentr
specif
immunoglobulin
igm
igg
concentr
titrat
use
antigen
microarray
develop
inhous
outbreak
sever
acut
respiratori
syndrom
sar
healthcar
worker
hcw
high
risk
infect
due
variou
clinic
present
infect
patient
andor
close
contact
care
although
much
learn
clinic
featur
diseas
well
characterist
caus
agent
coronaviru
treatment
includ
ribavirin
methylprednisolon
therapi
accord
immedi
patient
respons
also
document
unfortun
lack
clinic
proof
prevent
confirm
therapi
vitro
experi
determin
inhibitori
concentr
ribavirin
support
achiev
dose
due
limit
impos
cellular
toxic
human
bodi
although
lifethreaten
diseas
appear
control
follow
major
worldwid
effort
implement
quarantin
polici
return
sar
possibl
although
drug
anticoronaviru
cov
activ
identifi
yet
anticov
drug
approv
vaccin
yet
made
avail
previou
report
viral
infect
suggest
convalesc
plasma
serum
effect
treatment
avail
emerg
report
present
experi
convalesc
plasma
treatment
altern
clinic
improv
observ
use
standard
treatment
sarsinfect
hcw
april
major
outbreak
sar
declar
taipei
municip
hope
hospit
tmhh
larg
number
suspect
probabl
case
subsequ
transfer
redistribut
differ
hospit
quarantin
medic
care
transfer
tmhh
triservic
gener
hospit
tsgh
admit
suspect
case
emerg
depart
patient
transfer
tmhh
within
next
week
total
suspect
probabl
sar
case
admit
outbreak
total
hcw
physician
nurs
involv
patient
care
sar
isol
ward
sar
period
tsgh
five
confirm
case
tmhh
develop
respiratori
failur
admiss
two
ultim
expir
anticov
igg
antibodi
detect
indirect
immunofluoresc
assay
use
vero
cell
infect
strain
sarscov
genbank
access
isol
sar
patient
screen
test
perform
describ
previous
serum
specimen
test
dilut
posit
titer
test
repeat
specimen
titrat
endpoint
use
serial
dilut
titr
second
test
serum
sampl
perform
previous
obtain
serum
sampl
also
examin
sarscov
igg
serum
hcw
diagnos
probabl
sar
case
close
contact
blind
sent
depart
microbiolog
chines
univers
hong
kong
confirm
primer
probe
use
rtpcr
sarscov
detect
synthes
accord
recommend
center
diseas
control
prevent
cdc
atlanta
georgia
usa
viral
rna
throatswab
specimen
extract
use
magna
pure
lc
total
nucleic
acid
isol
kit
roch
mannheim
germani
extract
ml
rna
extract
use
templat
pcr
assay
ml
reaction
volum
contain
ml
buffer
ml
enzym
mix
ml
deoxynucleosid
triphosph
mm
sens
antisens
primer
reaction
subject
precycl
consist
c
min
c
min
forti
cycl
amplif
conduct
c
c
c
min
realtim
quantit
rtpcr
assay
ml
reaction
volum
contain
ml
human
pneumonia
associ
hpa
coronaviru
lc
master
mix
ml
hpacoronaviru
lc
mgsol
ml
hpacoronaviru
lc
intern
control
thermalcycl
use
light
cycler
roch
follow
c
min
rt
reaction
c
min
denatur
follow
cycl
amplif
consist
c
c
c
two
hcw
one
laboratori
research
becam
infect
result
involv
sar
patient
care
select
convalesc
plasma
transfus
failur
empir
treatment
use
ribavirin
methylprednisolon
commenc
emerg
approv
convalesc
plasma
transfus
clinic
trial
obtain
depart
health
follow
inform
consent
convalesc
plasma
obtain
marri
coupl
anoth
patient
one
index
case
tmhh
outbreak
other
recov
day
month
respect
sarscov
infect
donor
blood
type
seroneg
hepat
b
c
hiv
syphili
human
tcell
lymphotrop
viru
type
ii
htlvi
ii
serum
antibodi
igg
titr
apharesi
perform
cs
plu
cell
separ
baxter
deerfield
il
usa
follow
format
convalesc
phase
plasma
part
routin
check
plasma
donat
convalesc
plasma
also
confirm
free
residu
sarscov
rtpcr
serial
serum
sampl
obtain
recipi
convalesc
plasma
collect
conduct
realtim
quantit
rtpcr
sarscov
order
measur
viral
concentr
directli
previous
describ
specif
immunoglobulin
igm
igg
concentr
titrat
use
antigen
microarray
develop
inhous
briefli
purifi
recombin
nucleocapsid
protein
sarscov
differ
concentr
print
glass
microscop
slide
use
computercontrol
highspe
robot
cartesian
technolog
ca
usa
print
slide
incub
min
room
temperatur
solut
contain
wv
skim
milk
phosphatebuff
salin
pb
block
nonspecif
antibodi
bind
serum
sampl
dilut
pb
contain
wv
skim
milk
mll
tween
allow
react
array
min
room
temperatur
humid
chamber
reveal
igg
bind
print
antigen
slide
wash
five
time
ml
pb
contain
mll
tween
subsequ
incub
min
cy
antihuman
igg
monoclon
antibodi
suspend
solut
contain
pb
wv
nonfat
milk
mll
tween
reveal
igm
slide
incub
min
cy
goat
immunoglobulin
direct
antihuman
igm
chain
effici
label
procedur
assess
measur
molar
ratio
dye
protein
analys
scanner
genepix
axon
ca
usa
quantiti
igg
igm
sera
determin
interpol
photomultipli
count
collect
recombin
nucleocapsid
protein
spot
igg
igm
intern
calibr
curv
first
suspect
case
sarscov
infect
hcw
observ
intern
may
male
experienc
fever
c
sign
infect
pneumonia
diarrhoea
leucopenia
initi
selfquarantin
separ
dormitori
fever
subsid
day
rose
c
may
immedi
admit
isol
ward
cough
malais
rhinorrhoea
sore
throat
headach
subsequ
occur
deem
probabl
sar
case
quarantin
dormitori
two
nurs
direct
care
sar
patient
admit
isol
ward
may
sign
fever
myalgia
andor
headach
investig
outbreak
among
hcw
initi
total
hcw
quarantin
subsequ
fever
observ
anoth
three
nurs
resid
physician
period
may
tabl
apart
hcw
resid
request
selfquarantin
three
nurs
admit
immedi
experienc
fever
hcw
work
frequent
one
neg
pressur
ward
one
two
neg
pressur
ward
immedi
close
may
patient
close
ward
transfer
remain
neg
pressur
ward
case
fever
observ
hcw
thereaft
last
patient
isol
ward
hcw
discharg
june
specif
isol
ward
sar
close
day
last
patient
discharg
sar
case
note
subsequ
decemb
sarscov
research
experienc
fever
decemb
selfquarantin
fever
subsid
day
final
admit
probabl
sar
case
rtpcr
sputum
immedi
perform
admiss
research
confirm
posit
cov
infect
serum
infect
hcw
collect
week
serum
igg
antibodi
titr
rang
tabl
common
symptom
present
fever
bodi
temperatur
c
cough
chill
rhinorrhoea
sore
throat
vomit
none
hcw
present
diarrhoea
dyspnoea
admiss
howev
three
develop
maladi
day
fever
onset
four
hcw
abnorm
chest
radiograph
two
increas
lung
mark
two
patch
infiltr
empir
treatment
oral
ribavirin
mgday
moxifloxacin
mgday
commenc
day
admiss
hcw
research
methylprednisolon
mgkg
day
intraven
immunoglobulin
g
ivig
mgkgday
day
given
hcw
persist
chest
radiograph
progress
progress
pulmonari
infiltr
oxygen
desatur
convalesc
plasma
transfus
rate
mlmin
day
admiss
respect
laboratoryacquir
case
hcw
proteas
inhibitor
lopinavir
mgritonavir
h
convalesc
plasma
start
confirm
sarscov
infect
serial
chest
xray
reveal
progress
pulmonari
infiltr
five
hcw
becom
sever
day
fever
onset
one
hcw
experienc
least
two
fever
peak
three
fever
peak
observ
two
hcw
fail
respond
empir
treatment
develop
sever
progress
three
hcw
receiv
convalesc
plasma
transfus
two
due
sever
progress
involv
treatment
trial
serial
chest
radiograph
show
progress
pulmonari
infiltr
hcw
fail
respond
empir
treatment
day
convalesc
plasma
transfus
bodi
temperatur
decreas
c
radiolog
improv
also
observ
convalesc
plasma
transfus
pulmonari
opac
complet
resolv
hcw
discharg
realtim
quantit
sarscov
rna
measur
blood
sampl
reveal
high
viral
load
copiesml
respect
hcw
detect
h
convalesc
plasma
transfus
viral
load
longer
detect
sequenti
blood
sampl
h
transfus
although
detect
limit
viral
load
assay
presum
copi
per
assay
contrast
low
titr
igm
igg
observ
initi
sampl
transfus
increas
subsequ
timedepend
manner
tabl
thorac
ct
scan
pulmonari
function
test
diffus
capac
perform
hcw
pulmonari
fibrosi
mildli
restrict
ventilatori
impair
identifi
hcw
normal
pulmonari
function
diffus
capac
observ
post
discharg
hcw
subsequ
hcw
becam
pregnant
deliv
healthi
babi
month
discharg
antisarscov
igg
detect
mother
infant
deliveri
thu
suspect
passiv
transfer
antisarscov
antibodi
infant
rather
congenit
infect
infant
sinc
sar
epidem
clinic
treatment
prove
consist
effect
sarscov
infect
although
number
compound
vitro
activ
cov
identifi
clinic
data
use
compound
obtain
two
previou
report
convalesc
plasma
transfus
found
effect
patient
given
treatment
day
ill
seroconvers
studi
disclos
viru
clear
day
convalesc
plasma
transfus
follow
subsid
fever
resolut
pulmonari
infiltr
antisar
igm
igg
subsequ
document
transfus
signific
side
effect
found
although
favour
outcom
achiev
patient
role
effect
convalesc
plasma
therapi
remain
inconclus
sampl
size
studi
small
treatment
includ
ribavirin
methylprednisolon
ivig
proteas
inhibitor
also
use
concomitantli
confound
result
efficaci
convalesc
plasma
sar
infect
need
studi
surviv
two
hcw
laboratori
research
suggest
random
trial
therapi
ethic
accept
especi
individu
respond
ribavirin
methylprednison
sar
patient
develop
sever
progress
fail
respond
avail
treatment
altern
therapi
convalesc
plasma
transfus
may
consid
